Development of a Series of Pyrrolopyridone MAT2A Inhibitors

被引：5

作者：

Atkinson, Stephen J. ^{[1
]}

Bagal, Sharan K. ^{[1
]}

Argyrou, Argyrides ^{[1
,5
]}

Askin, Sean ^{[2
]}

Cheung, Tony ^{[3
]}

Chiarparin, Elisabetta ^{[1
]}

Coen, Muireann ^{[4
]}

Collie, Iain T. ^{[5
]}

Dale, Ian L. ^{[5
]}

De Fusco, Claudia ^{[5
]}

Dillman, Keith ^{[3
]}

Evans, Laura ^{[1
]}

Feron, Lyman J. ^{[1
]}

Foster, Alison J. ^{[4
]}

Grondine, Michael ^{[3
]}

Kantae, Vasudev ^{[5
]}

Lamont, Gillian M. ^{[1
]}

Lamont, Scott ^{[1
]}

Lynch, James T. ^{[1
]}

Lill, Sten Nilsson ^{[4
]}

Robb, Graeme R. ^{[1
]}

Saeh, Jamal ^{[3
]}

Schimpl, Marianne ^{[5
]}

Scott, James S. ^{[1
]}

Smith, James ^{[1
]}

Srinivasan, Bharath ^{[5
]}

Tentarelli, Sharon ^{[3
]}

Vazquez-Chantada, Mercedes ^{[5
]}

Wagner, David ^{[1
]}

Walsh, Jarrod J. ^{[5
]}

Watson, David ^{[1
]}

Williamson, Beth ^{[1
]}

机构：

[1] AstraZeneca, Discovery Ctr, Oncol R&D, Cambridge CB2 0AA, England

[2] AstraZeneca, Adv Drug Delivery, Pharmaceut Sci,R&D, Cambridge CB2 0AA, England

[3] AstraZeneca, Oncol R&D, R&D Boston, Waltham, MA 02451 USA

[4] Discovery Ctr, Clin Pharmacol & Safety Sci, R&D, AstraZeneca, Cambridge CB2 0AA, England

[5] Discovery Ctr, Discovery Sci R&D, AstraZeneca, Cambridge CB2 0AA, England

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2024年 / 67卷 / 06期

关键词：

S-ADENOSYLMETHIONINE; FREE-ENERGY; MTAP; METHIONINE; DISCOVERY;

D O I：

10.1021/acs.jmedchem.3c01860

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The optimization of an allosteric fragment, discovered by differential scanning fluorimetry, to an in vivo MAT2a tool inhibitor is discussed. The structure-based drug discovery approach, aided by relative binding free energy calculations, resulted in AZ'9567 (21), a potent inhibitor in vitro with excellent preclinical pharmacokinetic properties. This tool showed a selective antiproliferative effect on methylthioadenosine phosphorylase (MTAP) KO cells, both in vitro and in vivo, providing further evidence to support the utility of MAT2a inhibitors as potential anticancer therapies for MTAP-deficient tumors.

引用

页码：4541 / 4559

页数：19

共 50 条

[21] MAT2A as key regulator and therapeutic target in MLL leukemogenesis
Bloechl, B.
Secker, K. -A.
Keppeler, H.
Duerr-Stoerzer, S.
Schmid, H.
Jeong, J.
Mankel, B.
Fend, F.
Schneidawind, D.
Schneidawind, C.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 26 - 26
[22] MAT2A inhibition combats metabolic and transcriptional reprogramming in cancer
Pulous, Fadi E.
Steurer, Barbara
Pun, Frank W.
Zhang, Man
Ren, Feng
Zhavoronkov, Alex
DRUG DISCOVERY TODAY, 2024, 29 (11)
[23] Targeting MAT2A in CDKN2A/MTAP-deleted cancers
Marjon, Katya
Kalev, Peter
Hyer, Marc
Fletcher, Mark
Zhang, Peili
Aguado-Fraile, Elia
Mandley, Everton
Konteatis, Zenon
Travins, Jeremy
Marks, Kevin
CANCER RESEARCH, 2019, 79 (13)
[24] Autophagy regulates MAT2A in response to hypoxia in pancreatic cancer cells
Yang, Yang
Wang, Wenping
Rademaker, Gilles
Ravichandran, Mirunalini
Hu, Jingjie
Li, Alexander
Mancias, Joseph D.
Guo, Jessie Yanxiang
Perera, Rushika M.
CANCER RESEARCH, 2024, 84 (02)
[25] MAT2B regulates the protein level of MAT2A to preserve RNA N6-methyladenosine
Wan, Xinyi
Zeng, Weiwu
Fan, Haonan
Wang, Chenliang
Han, Shixun
Sun, Zhongxing
Tang, Mei
Shao, Juejia
Liu, Yu
Fang, Yuan
Jia, Junqi
Tang, Yin
Zhang, Yanjun
Zhao, Bin
Fang, Dong
CELL DEATH & DISEASE, 2024, 15 (10):
[26] SAM homeostasis is regulated by CFIm-mediated splicing of MAT2A
Scarborough, Anna M.
Flaherty, Juliana N.
Hunter, Olga, V
Liu, Kuanqing
Kumar, Ashwani
Xing, Chao
Tu, Benjamin P.
Conrad, Nicholas K.
ELIFE, 2021, 10
[27] PPARγ induces the paroxysm of endometriosis by regulating the transcription of MAT2A gene
Zhang, Shun
Zhuang, Lingling
Liu, Qian
Yu, Xiaolin
Min, Qinghua
Chen, Minjie
Chen, Qi
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (03): : 1377 - 1388
[28] Balance between MAT2A intron detention and splicing is determined cotranscriptionally
Pendleton, Kathryn E.
Park, Sung-Kyun
Hunter, Olga, V
Bresson, Stefan M.
Conrad, Nicholas K.
RNA, 2018, 24 (06) : 778 - 786
[29] Mitotic defects induced by MAT2A inhibitors guides translational drug combination strategies with AG-270 and taxanes
Kalev, Peter
Hyer, Marc L.
Fletcher, Mark
Zhang, Peili
Aguado-Fraile, Elia
Mandley, Everton
Tuncay, Yesim
Konteatis, Zenon
Travins, Jeremy
Marks, Kevin M.
Marjon, Katya
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
[30] Discovery of Novel Spirocyclic MAT2A Inhibitors Demonstrating High In Vivo Efficacy in MTAP-Null Xenograft Models
Yang, Sai
Gu, Xiaowen
Chen, Lei
Zhu, Weixing
JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (03) : 3480 - 3494

← 1 2 3 4 5 →